a
Neurosurgery has published a peer-reviewed article regarding the cost-effectiveness of LDR's Mobi-C Cervical Disc.
Friedberg Investment Management has lowered its position in K2M Group stock by 8.2 percent during the fourth quarter, according to an Intercooler report.

3. Amedica shares soar by 2k+%: 5 things to know

Written by Anuja Vaidya | Wednesday, 10 February 2016 00:00
Amedica shares increased by 2,200.88% in the last 20 days, according to an FDA News Alert report.
Tyber Medical released its TyWedge Osteotomy Wedge Systems.

5. Analysts weigh in on Stryker shares: 5 notes

Written by Mary Rechtoris | Wednesday, 10 February 2016 00:00
Analysts gave Stryker shares a mean rating of 2.1, according to CWRU Observer.

6. Analysts expect decline in NuVasive's EPS growth: 4 notes

Written by Mary Rechtoris | Wednesday, 10 February 2016 00:00
Analysts forecast NuVasive will report negative EPS growth for the fourth quarter of 2015, according to WallStreet.org.
The global spinal trauma devices market is expected to grow due to an increasing number of traffic accidents, geriatric population and number of trauma care centers.

8. Alphatec Holdings downgraded to 'sell' rating: 5 points

Written by Megan Wood | Wednesday, 10 February 2016 00:00
Northland Securities downgraded Alphatec Holdings' shares from an "outperform" rating to a "sell" rating on Feb. 9, according to The Vista Voice.

9. Misonix releases Q2 2016 results — 5 highlights

Written by Megan Wood | Wednesday, 10 February 2016 00:00
Farmingdale, N.Y.-based Misonix released its financial results for the second quarter of fiscal year 2016, ending Dec. 31, 2015.
Obtaining reimbursement for new spine surgery technology isn't a walk in the park. There are instances where a new technology receives FDA clearance, support from spine societies, a Category 1 CPT code and coverage by Medicare and Medicaid, and a number of articles detailing clinical evidence supporting use of the technology is published, yet commercial insurance companies still question the procedure.
Stryker plans to acquire Synergetics USA's neuro portfolio.

12. NuVasive establishes new 52-week low: 4 points

Written by Anuja Vaidya | Tuesday, 09 February 2016 00:00
NuVasive reached a new 52-week low on Feb. 8, according to Equities.com.
OrthAlign has entered into a multi-country distribution agreement with Smith & Nephew.
Rick Pospisil, MD, of Huntington Beach (Calif.), is offering patients procedures to treat carpal tunnel syndrome.
Oppenheimer analysts reaffirmed Zimmer Biomet's "outperform" rating, according to Wallstreet.org.
At the Arab Health Exhibition and Congress in Dubai, Medtronic launched its Valleylab FT10 energy platform, according to Trade Arabia.

17. Ellipse Technologies' IPO is no more: 5 key notes

Written by Laura Dyrda | Tuesday, 09 February 2016 00:00
Ellipse Technologies withdrew its initial public offering yesterday, according to a Renaissance Capital report.
Amedica is now in compliance with NASDAQ listing requirements after a period last year where the company's share price dipped below $1.

19. Zacks upgrades Cytori Therapeutics to 'buy' rating: 6 insights

Written by Megan Wood | Tuesday, 09 February 2016 00:00
Zacks upgraded San Diego-based Cytori Therapeutics to a "buy" rating from a "hold" rating on Feb. 9, according to InterCooler.

20. 4 observations of newly developed 'bionic spine'

Written by Megan Wood | Tuesday, 09 February 2016 00:00
Australian researchers invented a "bionic spine" for paraplegics, according to Fox News Healthth.
  • «
  •  Prev 
  •  1 
  •  2 
  •  3 
  •  4 
  •  5 
  •  6 
  •  7 
  •  8 
  •  9 
  •  10 
  •  Next 
  • »
Page 1 of 273

Top 40 Articles from the Past 6 Months